Chimeros chimeros.com


Public lists: Pharma Startups (4732)

Chimeros is developing a biologics approach to enable delivery of polynucleotide therapeutics such as siRNAs. The company's delivery technology, termed Chimerasomes, is based upon protein building blocks that can bind these therapeutic payloads and subsequently be triggered to self-assemble into nanocages, thereby encapsulating the polynucleic acids. The surface of the nanocages can subsequently be decorated with targeting moieties such as antibodies or with PK/ biodistribution modulating molecu...Show all

Chimeros is developing a biologics approach to enable delivery of polynucleotide therapeutics such as siRNAs. The company's delivery technology, termed Chimerasomes, is based upon protein building blocks that can bind these therapeutic payloads and s...Show all

Company (Alive / Active)

Phone: 858-622-0796

Fax:

3030 Bunker Hill Street
Suite 102
San Diego, 92109
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Chimeros $9.9M Aug 10, 2011
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Chimeros Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 4 investors

Competitors

Company Status Description Investors

MacroGenics

Rockville, Maryland, United States
IPO / Went publicMacroGenics is a biotechnology company focused on the discovery, development and delivery to patients of biologics for treatment of cancer, autoimmune disorders and infectious diseases. MacroGenics has built a fully-integrated set of capabilities in antibody-based product development which supports its innovative pipeline of clinical stage product candidates. MacroGenics' research is based on three core technology platforms, which include: (1) a leading research capability for screening and tar...Show allLogin to see details

Cara Therapeutics

Shelton, Connecticut, United States
IPO / Went publicCara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patented compound, CR845, is currently undergoing clinical testing for acute pain. This compound possesses analgesic and anti-inflammatory activities appropriate for mul...Show allLogin to see details
See all 16 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Compositions and methods for treating b-cell malignancies Apr 09, 2007 Nov 29, 2011 Patent
Self-assembling nanoparticle drug delivery system May 25, 2005 Jun 21, 2011 Patent